



Introducing Equitable Oncology

Helping more people access cancer treatment.

Every day, people miss out on the opportunity to benefit from advances in cancer treatment. Often, not because the science doesn't exist, but because treatment is too expensive or too difficult to access.

Scientific innovation continues to transform what is possible in cancer treatment. Yet for many people, these advances remain out of reach.

The cost of a treatment is only part of the challenge. Where people live, the healthcare services available to them and how a treatment needs to be delivered can all influence whether someone is able to access it. For patients and their families, the financial burden can also extend beyond the cost of treatment itself to include travel, accommodation, time away from work and other costs associated with receiving care.

Today marks the launch of Equitable Oncology, an independently governed New Zealand registered charity established to improve equitable access to cancer treatment.

our mission:

Helping more people access cancer treatment.

a different approach

Many organisations are working to improve access to cancer treatments available today. Equitable Oncology complements these efforts by focusing on how tomorrow's cancer treatments are developed and funded.

At the heart of our work is a powerful insight:

The way a treatment is developed and funded influences who can ultimately benefit from it. Decisions made throughout development can influence the future cost, manufacture, storage, delivery and accessibility of a treatment.

By considering cost and access alongside scientific excellence from the outset, there is an opportunity to reduce barriers before they become embedded.

the Equitable Oncology Model

The Equitable Oncology Model brings together people, expertise, resources and funding to support the advancement of innovative cancer treatments that have the potential to be more affordable and accessible.

Rather than bringing all of the expertise needed to advance and deliver cancer treatments into one organisation, Equitable Oncology brings together existing capability around a shared purpose.



Researchers, clinicians, healthcare providers, industry, philanthropists, philanthropic organisations, governments, patients and advocacy organisations each bring valuable expertise and have an important role to play. Philanthropy is central to this approach.

Philanthropic funding supports the advancement of cancer treatments where affordability and accessibility have already been considered alongside scientific excellence. By funding development and related costs, philanthropy can reduce the amount that ultimately needs to be recovered through the treatment price.

In this way, philanthropy has the potential to influence patient access long before a new treatment reaches them.

The Equitable Oncology Model also creates the opportunity for philanthropy to have an impact more than once.


Where appropriate, Equitable Oncology may take an equity interest in some of the partnerships it supports. Future income generated through these interests can be reinvested in Equitable Oncology's charitable mission, creating the potential for philanthropic support to help create value that can, over time, further advance our mission.

our lead programme: K5K

K5K is the first clinical programme being advanced through the Equitable Oncology Model.

K5K builds on more than three decades of scientific research and clinical and translational experience with Kode Immuno-Educers (KIEs).

a strong scientific foundation



AGI-134, a second-generation KIE, progressed to a Phase 1/2a human clinical study, with positive clinical findings providing important human experience with the KIE approach. Kv9, a third-generation KIE using the same underlying molecule as K5K, is being evaluated in veterinary oncology across multiple solid tumour types, with preliminary anti-tumour responses observed.

Together, this scientific, clinical and translational experience provides a strong foundation for the progression of K5K into human clinical development. From the outset, K5K has been designed with affordability and accessibility considered alongside scientific excellence.

Its design includes a target treatment cost of less than USD \$5,000 per course and stability at temperatures above 40°C, helping reduce the need for refrigeration and making treatment easier to store and deliver in different healthcare settings.

K5K therefore represents more than the advancement of one potential cancer treatment. It is the first opportunity to demonstrate the Equitable Oncology Model in practice.

building the future

The launch of Equitable Oncology marks the beginning of the next stage of our work. Our immediate focus is advancing K5K towards first-in-human clinical trials once funding is secured, while continuing to build the partnerships, philanthropic support and capability needed to put the Equitable Oncology Model into practice.

Over time, the Model has the potential to support other innovative cancer treatments that meet Equitable Oncology's criteria for affordability and accessibility.

We are inviting people and organisations who share our mission to become part of that work.

Whether through philanthropy, partnership, scientific and clinical expertise, advocacy or other support, there are many ways to contribute.

Together, we can help more people benefit from advances in cancer treatment. Explore Equitable Oncology and discover how you can become involved.



Contact Equitable Oncology
Christine Gill, Chief Executive Officer
Email: info@equitableoncology.com
Web: www.equitableoncology.com

